{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T17:58:08Z","timestamp":1791136688877,"version":"4.1.0"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,2,14]],"date-time":"2014-02-14T00:00:00Z","timestamp":1392336000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["AAPS J"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1208\/s12248-014-9577-8","type":"journal-article","created":{"date-parts":[[2014,2,13]],"date-time":"2014-02-13T21:36:47Z","timestamp":1392327407000},"page":"379-391","source":"Crossref","is-referenced-by-count":43,"title":["Determination of the Most Influential Sources of Variability in Tacrolimus Trough Blood Concentrations in Adult Liver Transplant Recipients: A Bottom-Up Approach"],"prefix":"10.1208","volume":"16","author":[{"given":"C\u00e9cile","family":"G\u00e9rard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanick","family":"Stocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Hulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Blanchet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9line","family":"Verstuyft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Durand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filomena","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Duvoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Tod","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,2,14]]},"reference":[{"issue":"9","key":"9577_CR1","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.7164\/antibiotics.40.1249","volume":"40","author":"T Kino","year":"1987","unstructured":"Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot (Tokyo). 1987;40(9):1249\u201355.","journal-title":"J Antibiot (Tokyo)"},{"issue":"9","key":"9577_CR2","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.7164\/antibiotics.40.1256","volume":"40","author":"T Kino","year":"1987","unstructured":"Kino T, Hatanaka H, Miyata S, Inamura N, Nishiyama M, Yajima T, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro. J Antibiot (Tokyo). 1987;40(9):1256\u201365.","journal-title":"J Antibiot (Tokyo)"},{"issue":"6","key":"9577_CR3","doi-asserted-by":"crossref","first-page":"404","DOI":"10.2165\/00003088-199529060-00003","volume":"29","author":"R Venkataramanan","year":"1995","unstructured":"Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995;29(6):404\u201330.","journal-title":"Clin Pharmacokinet"},{"issue":"1\u20132","key":"9577_CR4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0009-8981(01)00678-7","volume":"313","author":"SH Wong","year":"2001","unstructured":"Wong SH. Therapeutic drug monitoring for immunosuppressants. Clin Chim Acta. 2001;313(1\u20132):241\u201353.","journal-title":"Clin Chim Acta"},{"issue":"10","key":"9577_CR5","doi-asserted-by":"crossref","first-page":"623","DOI":"10.2165\/00003088-200443100-00001","volume":"43","author":"CE Staatz","year":"2004","unstructured":"Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43(10):623\u201353.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"9577_CR6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/FTD.0b013e318198d092","volume":"31","author":"P Wallemacq","year":"2009","unstructured":"Wallemacq P, Armstrong VW, Brunet M, Haufroid V, Holt DW, Johnston A, et al. Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit. 2009;31(2):139\u201352.","journal-title":"Ther Drug Monit"},{"issue":"10","key":"9577_CR7","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1111\/j.1600-6143.2012.04140.x","volume":"12","author":"M Rodriguez-Peralvarez","year":"2012","unstructured":"Rodriguez-Peralvarez M, Germani G, Darius T, Lerut J, Tsochatzis E, Burroughs AK. Tacrolimus trough levels, rejection and renal impairment in liver transplantation: a systematic review and meta-analysis. Am J Transplant. 2012;12(10):2797\u2013814.","journal-title":"Am J Transplant"},{"key":"9577_CR8","doi-asserted-by":"crossref","unstructured":"Rodriguez-Peralvarez M, Germani G, Papastergiou V, Tsochatzis E, Thalassinos E, Luong TV, et al. Early tacrolimus exposure after liver transplantation: relationship with moderate\/severe acute rejection and long-term outcome. J Hepatol. 2012 Sep 27.","DOI":"10.1016\/j.jhep.2012.09.019"},{"issue":"4","key":"9577_CR9","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/00007890-199402270-00008","volume":"57","author":"L Backman","year":"1994","unstructured":"Backman L, Nicar M, Levy M, Distant D, Eisenstein C, Renard T, et al. FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects. Transplantation. 1994;57(4):519\u201325.","journal-title":"Transplantation"},{"issue":"5","key":"9577_CR10","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1177\/00912700122010429","volume":"41","author":"R Venkataramanan","year":"2001","unstructured":"Venkataramanan R, Shaw LM, Sarkozi L, Mullins R, Pirsch J, MacFarlane G, et al. Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharmacol. 2001;41(5):542\u201351.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"9577_CR11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/11317350-000000000-00000","volume":"49","author":"CE Staatz","year":"2010","unstructured":"Staatz CE, Goodman LK, Tett SE. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin Pharmacokinet. 2010;49(3):141\u201375.","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"9577_CR12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.clpt.2006.06.008","volume":"80","author":"M Fukudo","year":"2006","unstructured":"Fukudo M, Yano I, Masuda S, Goto M, Uesugi M, Katsura T, et al. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin Pharmacol Ther. 2006;80(4):331\u201345.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"9577_CR13","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S0009-9236(03)00168-1","volume":"74","author":"DA Hesselink","year":"2003","unstructured":"Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 2003;74(3):245\u201354.","journal-title":"Clin Pharmacol Ther"},{"issue":"8","key":"9577_CR14","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/01.TP.0000090753.99170.89","volume":"76","author":"E Thervet","year":"2003","unstructured":"Thervet E, Anglicheau D, King B, Schlageter MH, Cassinat B, Beaune P, et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation. 2003;76(8):1233\u20135.","journal-title":"Transplantation"},{"issue":"4","key":"9577_CR15","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/86882","volume":"27","author":"P Kuehl","year":"2001","unstructured":"Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27(4):383\u201391.","journal-title":"Nat Genet"},{"issue":"8","key":"9577_CR16","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/00008571-200211000-00004","volume":"12","author":"JG Blanco","year":"2002","unstructured":"Blanco JG, Edick MJ, Hancock ML, Winick NJ, Dervieux T, Amylon MD, et al. Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics. 2002;12(8):605\u201311.","journal-title":"Pharmacogenetics"},{"issue":"7","key":"9577_CR17","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.1073\/pnas.97.7.3473","volume":"97","author":"S Hoffmeyer","year":"2000","unstructured":"Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A. 2000;97(7):3473\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9577_CR18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1146\/annurev.pharmtox.39.1.361","volume":"39","author":"SV Ambudkar","year":"1999","unstructured":"Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol. 1999;39:361\u201398.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"9","key":"9577_CR19","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/S0021-9258(18)53221-X","volume":"268","author":"T Saeki","year":"1993","unstructured":"Saeki T, Ueda K, Tanigawara Y, Hori R, Komano T. Human P-glycoprotein transports cyclosporin A and FK506. J Biol Chem. 1993;268(9):6077\u201380.","journal-title":"J Biol Chem"},{"issue":"6","key":"9577_CR20","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1097\/00007890-200109270-00013","volume":"72","author":"CE Staatz","year":"2001","unstructured":"Staatz CE, Taylor PJ, Lynch SV, Willis C, Charles BG, Tett SE. Population pharmacokinetics of tacrolimus in children who receive cut-down or full liver transplants. Transplantation. 2001;72(6):1056\u201361.","journal-title":"Transplantation"},{"issue":"13","key":"9577_CR21","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2165\/00003088-200342130-00006","volume":"42","author":"M Fukudo","year":"2003","unstructured":"Fukudo M, Yano I, Fukatsu S, Saito H, Uemoto S, Kiuchi T, et al. Forecasting of blood tacrolimus concentrations based on the Bayesian method in adult patients receiving living-donor liver transplantation. Clin Pharmacokinet. 2003;42(13):1161\u201378.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"9577_CR22","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1053\/jlts.2003.50023","volume":"9","author":"CE Staatz","year":"2003","unstructured":"Staatz CE, Willis C, Taylor PJ, Lynch SV, Tett SE. Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. Liver Transpl. 2003;9(2):130\u20137.","journal-title":"Liver Transpl"},{"issue":"5\u20136","key":"9577_CR23","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00228-005-0933-6","volume":"61","author":"M Antignac","year":"2005","unstructured":"Antignac M, Hulot JS, Boleslawski E, Hannoun L, Touitou Y, Farinotti R, et al. Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance. Eur J Clin Pharmacol. 2005;61(5\u20136):409\u201316.","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"9577_CR24","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1097\/FTD.0b013e318178e31b","volume":"30","author":"B Blanchet","year":"2008","unstructured":"Blanchet B, Duvoux C, Costentin CE, Barrault C, Ghaleh B, Salvat A, et al. Pharmacokinetic\u2013pharmacodynamic assessment of tacrolimus in liver-transplant recipients during the early post-transplantation period. Ther Drug Monit. 2008;30(4):412\u20138.","journal-title":"Ther Drug Monit"},{"issue":"3","key":"9577_CR25","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00228-011-1129-x","volume":"68","author":"I Yano","year":"2012","unstructured":"Yano I, Masuda S, Egawa H, Sugimoto M, Fukudo M, Yoshida Y, et al. Significance of trough monitoring for tacrolimus blood concentration and calcineurin activity in adult patients undergoing primary living-donor liver transplantation. Eur J Clin Pharmacol. 2012;68(3):259\u201366.","journal-title":"Eur J Clin Pharmacol"},{"issue":"3","key":"9577_CR26","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1038\/clpt.2012.109","volume":"92","author":"H Jonge de","year":"2012","unstructured":"de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR. In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. Clin Pharmacol Ther. 2012;92(3):366\u201375.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"9577_CR27","doi-asserted-by":"crossref","first-page":"53","DOI":"10.2133\/dmpk.24.53","volume":"24","author":"M Jamei","year":"2009","unstructured":"Jamei M, Dickinson GL, Rostami-Hodjegan A. A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: a tale of \u2018bottom-up\u2019 vs \u2018top-down\u2019 recognition of covariates. Drug Metab Pharmacokinet. 2009;24(1):53\u201375.","journal-title":"Drug Metab Pharmacokinet"},{"issue":"9","key":"9577_CR28","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/bdd.777","volume":"32","author":"H Ohtani","year":"2011","unstructured":"Ohtani H, Barter Z, Minematsu T, Makuuchi M, Sawada Y, Rostami-Hodjegan A. Bottom-up modeling and simulation of tacrolimus clearance: prospective investigation of blood cell distribution, sex and CYP3A5 expression as covariates and assessment of study power. Biopharm Drug Dispos. 2011;32(9):498\u2013506.","journal-title":"Biopharm Drug Dispos"},{"key":"9577_CR29","volume-title":"MONOLIX (MOd\u00e8les NOn LIn\u00e9aires \u00e0 effets miXtes)","author":"M Lavielle","year":"2008","unstructured":"Lavielle M. MONOLIX (MOd\u00e8les NOn LIn\u00e9aires \u00e0 effets miXtes). Orsay: MONOLIX group; 2008."},{"issue":"5","key":"9577_CR30","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/BF01061469","volume":"20","author":"JW Mandema","year":"1992","unstructured":"Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic\u2013pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm. 1992;20(5):511\u201328.","journal-title":"J Pharmacokinet Biopharm"},{"key":"9577_CR31","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1472-6904-2-5","volume":"2","author":"DG Levitt","year":"2002","unstructured":"Levitt DG. PKQuest: a general physiologically based pharmacokinetic model. Introduction and application to propranolol. BMC Clin Pharmacol. 2002;2:5.","journal-title":"BMC Clin Pharmacol"},{"issue":"1","key":"9577_CR32","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2253-5-4","volume":"5","author":"DG Levitt","year":"2005","unstructured":"Levitt DG, Schnider TW. Human physiologically based pharmacokinetic model for propofol. BMC Anesthesiol. 2005;5(1):4.","journal-title":"BMC Anesthesiol"},{"issue":"6","key":"9577_CR33","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/BF01059688","volume":"5","author":"KS Pang","year":"1977","unstructured":"Pang KS, Rowland M. Hepatic clearance of drugs. I. Theoretical considerations of a \u201cwell-stirred\u201d model and a \u201cparallel tube\u201d model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm. 1977;5(6):625\u201353.","journal-title":"J Pharmacokinet Biopharm"},{"key":"9577_CR34","unstructured":"Tacrolimus. 2012 [updated 2012; cited May 22, 2012]; Available from: http:\/\/www.drugbank.ca\/drugs\/DB00864 ."},{"issue":"3","key":"9577_CR35","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0009-9236(95)90153-1","volume":"57","author":"WJ Jusko","year":"1995","unstructured":"Jusko WJ, Piekoszewski W, Klintmalm GB, Shaefer MS, Hebert MF, Piergies AA, et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther. 1995;57(3):281\u201390.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"9577_CR36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1056-8719(02)00158-2","volume":"46","author":"H Zahir","year":"2001","unstructured":"Zahir H, Nand RA, Brown KF, Tattam BN, McLachlan AJ. Validation of methods to study the distribution and protein binding of tacrolimus in human blood. J Pharmacol Toxicol Methods. 2001;46(1):27\u201335.","journal-title":"J Pharmacol Toxicol Methods"},{"issue":"8","key":"9577_CR37","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2165\/00003088-200746080-00005","volume":"46","author":"Y Ohno","year":"2007","unstructured":"Ohno Y, Hisaka A, Suzuki H. General framework for the quantitative prediction of CYP3A4-mediated oral drug interactions based on the AUC increase by coadministration of standard drugs. Clin Pharmacokinet. 2007;46(8):681\u201396.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"9577_CR38","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1365-2125.2008.03188.x","volume":"66","author":"S Satoh","year":"2008","unstructured":"Satoh S, Kagaya H, Saito M, Inoue T, Miura M, Inoue K, et al. Lack of tacrolimus circadian pharmacokinetics and CYP3A5 pharmacogenetics in the early and maintenance stages in Japanese renal transplant recipients. Br J Clin Pharmacol. 2008;66(2):207\u201314.","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"9577_CR39","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1124\/dmd.105.008680","volume":"34","author":"Y Dai","year":"2006","unstructured":"Dai Y, Hebert MF, Isoherranen N, Davis CL, Marsh C, Shen DD, et al. Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro. Drug Metab Dispos. 2006;34(5):836\u201347.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"9577_CR40","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s12185-009-0344-z","volume":"90","author":"T Mori","year":"2009","unstructured":"Mori T, Aisa Y, Kato J, Nakamura Y, Ikeda Y, Okamoto S. Drug interaction between oral solution itraconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplantation recipients: an association with bioavailability of oral solution itraconazole. Int J Hematol. 2009;90(1):103\u20137.","journal-title":"Int J Hematol"},{"issue":"6","key":"9577_CR41","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1592\/phco.27.6.825","volume":"27","author":"A Sansone-Parsons","year":"2007","unstructured":"Sansone-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant TG. Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy. 2007;27(6):825\u201334.","journal-title":"Pharmacotherapy"},{"issue":"11","key":"9577_CR42","doi-asserted-by":"crossref","first-page":"813","DOI":"10.2165\/00003088-200241110-00003","volume":"41","author":"U Christians","year":"2002","unstructured":"Christians U, Jacobsen W, Benet LZ, Lampen A. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet. 2002;41(11):813\u201351.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"9577_CR43","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1079\/BJN19910073","volume":"65","author":"P Deurenberg","year":"1991","unstructured":"Deurenberg P, Weststrate JA, Seidell JC. Body mass index as a measure of body fatness: age- and sex-specific prediction formulas. Br J Nutr. 1991;65(2):105\u201314.","journal-title":"Br J Nutr"},{"key":"9577_CR44","volume-title":"ADAPT II user\u2019s guide. Pharmacokinetic\/Pharmacodynamic Systems Analysis Software","author":"D D'Argenio","year":"1997","unstructured":"D'Argenio D, Schumitzky A. ADAPT II user\u2019s guide. Pharmacokinetic\/Pharmacodynamic Systems Analysis Software. Los Angeles: Biomedical Simulations Resource; 1997."},{"issue":"4","key":"9577_CR45","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s10928-010-9165-1","volume":"37","author":"S Pilari","year":"2010","unstructured":"Pilari S, Huisinga W. Lumping of physiologically-based pharmacokinetic models and a mechanistic derivation of classical compartmental models. J Pharmacokinet Pharmacodyn. 2010;37(4):365\u2013405.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"9577_CR46","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/cpt1975184377","volume":"18","author":"GR Wilkinson","year":"1975","unstructured":"Wilkinson GR, Shand DG. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther. 1975;18(4):377\u201390.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"9577_CR47","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1432-2277.2011.01365.x","volume":"25","author":"A Capron","year":"2011","unstructured":"Capron A, Lerut J, Latinne D, Rahier J, Haufroid V, Wallemacq P. Correlation of tacrolimus levels in peripheral blood mononuclear cells with histological staging of rejection after liver transplantation: preliminary results of a prospective study. Transpl Int. 2011;25(1):41\u20137.","journal-title":"Transpl Int"},{"issue":"6\u20137","key":"9577_CR48","first-page":"479","volume":"57","author":"S Fukatsu","year":"2001","unstructured":"Fukatsu S, Yano I, Igarashi T, Hashida T, Takayanagi K, Saito H, et al. Population pharmacokinetics of tacrolimus in adult recipients receiving living-donor liver transplantation. Eur J Clin Pharmacol. 2001;57(6\u20137):479\u201384.","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"9577_CR49","first-page":"1093","volume":"28","author":"A Provenzani","year":"2011","unstructured":"Provenzani A, Notarbartolo M, Labbozzetta M, Poma P, Vizzini G, Salis P, et al. Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients. Int J Mol Med. 2011;28(6):1093\u2013102.","journal-title":"Int J Mol Med"},{"issue":"5","key":"9577_CR50","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1365-2710.2007.00850.x","volume":"32","author":"D Li","year":"2007","unstructured":"Li D, Lu W, Zhu JY, Gao J, Lou YQ, Zhang GL. Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients. J Clin Pharm Ther. 2007;32(5):505\u201315.","journal-title":"J Clin Pharm Ther"},{"issue":"5","key":"9577_CR51","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1097\/FPC.0b013e3282f9ac01","volume":"18","author":"M Fukudo","year":"2008","unstructured":"Fukudo M, Yano I, Yoshimura A, Masuda S, Uesugi M, Hosohata K, et al. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics. 2008;18(5):413\u201323.","journal-title":"Pharmacogenet Genomics"},{"issue":"10","key":"9577_CR52","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1097\/00007890-200211270-00014","volume":"74","author":"T Shimada","year":"2002","unstructured":"Shimada T, Terada A, Yokogawa K, Kaneko H, Nomura M, Kaji K, et al. Lowered blood concentration of tacrolimus and its recovery with changes in expression of CYP3A and P-glycoprotein after high-dose steroid therapy. Transplantation. 2002;74(10):1419\u201324.","journal-title":"Transplantation"},{"issue":"11","key":"9577_CR53","doi-asserted-by":"crossref","first-page":"741","DOI":"10.2165\/00003088-200443110-00005","volume":"43","author":"DR Kuypers","year":"2004","unstructured":"Kuypers DR, Claes K, Evenepoel P, Maes B, Coosemans W, Pirenne J, et al. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet. 2004;43(11):741\u201362.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"9577_CR54","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1046\/j.1365-2125.2003.02008.x","volume":"57","author":"H Zahir","year":"2004","unstructured":"Zahir H, McCaughan G, Gleeson M, Nand RA, McLachlan AJ. Factors affecting variability in distribution of tacrolimus in liver transplant recipients. Br J Clin Pharmacol. 2004;57(3):298\u2013309.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"9577_CR55","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/bja\/65.3.418","volume":"65","author":"AM Burns","year":"1990","unstructured":"Burns AM, Shelly MP, Walker S, Park GR. Serum acute phase proteins after orthotopic liver transplantation. Br J Anaesth. 1990;65(3):418\u201320.","journal-title":"Br J Anaesth"},{"issue":"1","key":"9577_CR56","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00007890-199107000-00015","volume":"52","author":"K Abu-Elmagd","year":"1991","unstructured":"Abu-Elmagd K, Fung JJ, Alessiani M, Jain A, Venkataramanan R, Warty VS, et al. The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation. 1991;52(1):71\u20137.","journal-title":"Transplantation"},{"issue":"7","key":"9577_CR57","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1002\/j.1552-4604.1993.tb04712.x","volume":"33","author":"AB Jain","year":"1993","unstructured":"Jain AB, Abu-Elmagd K, Abdallah H, Warty V, Fung J, Todo S, et al. Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion. J Clin Pharmacol. 1993;33(7):606\u201311.","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"9577_CR58","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1432-2277.1994.tb01242.x","volume":"7","author":"M Winkler","year":"1994","unstructured":"Winkler M, Ringe B, Rodeck B, Melter M, Stoll K, Baumann J, et al. The use of plasma levels for FK 506 dosing in liver-grafted patients. Transpl Int. 1994;7(5):329\u201333.","journal-title":"Transpl Int"},{"issue":"5","key":"9577_CR59","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1079\/BJN20041273","volume":"92","author":"M Arroyo","year":"2004","unstructured":"Arroyo M, Rocandio AM, Ansotegui L, Herrera H, Salces I, Rebato E. Comparison of predicted body fat percentage from anthropometric methods and from impedance in university students. Br J Nutr. 2004;92(5):827\u201332.","journal-title":"Br J Nutr"},{"key":"9577_CR60","unstructured":"VIDAL. PROGRAF\u00ae G\u00e9lules [database on the Internet]. 2012 [cited 03\/08\/2012]. Available from: http:\/\/www.vidalpro.net\/medicaments\/front\/recherchemedic.asp?site=2&cartouche=17&id=41863&lib=PROGRAF+1+mg+g%E9l+%3A+Plq%2F50&type=spe ."},{"issue":"6","key":"9577_CR61","first-page":"721","volume":"87","author":"E Thervet","year":"2010","unstructured":"Thervet E, Loriot MA, Barbier S, Buchler M, Ficheux M, Choukroun G, et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin Pharmacol Ther. 2010;87(6):721\u20136.","journal-title":"Clin Pharmacol Ther"}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-014-9577-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1208\/s12248-014-9577-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-014-9577-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,26]],"date-time":"2022-03-26T15:15:14Z","timestamp":1648307714000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1208\/s12248-014-9577-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,2,14]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["9577"],"URL":"https:\/\/doi.org\/10.1208\/s12248-014-9577-8","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,2,14]]}}}